Sermorelin's Pharmacological Background A 2002 Endocrine Practice review confirmed that Sermorelin (brand name Geref, discontinued) produced statistically significant increases in IGF-1 and lean body mass in adults with growth hormone deficiency, using doses of 0.2 to 0.3 mg administered subcutaneously each evening [2]
The risk of fat buildup, known as fatty liver disease, can be reduced by improving the livers efficiency in processing fats and toxins
In recent years, targeted regulation of cellular metabolic pathways has become a central focus of anti-aging research
Order Tracking Once your order has shipped, you'll receive a shipping confirmation email with tracking information so you can monitor your delivery
Without medical supervision, adverse effects cannot be appropriately monitored or managed
After 28 days, discard the contents regardless of how much remains